Ondine Biopharma Completes Private Placement Equity Financing

 
TIDMOBP 
 
Ondine Biopharma Completes Private Placement Equity Financing 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
April 26, 2010 
 
Ondine Biopharma Completes Private Placement Equity Financing 
 
VANCOUVER, BRITSH COLUMBIA--(Marketwire - April 26, 2010) - 
 
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES 
 
Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the "Company") a medical technology company developing 
photodisinfection based products today announced it has completed its non-brokered private placement (the 
"Placement") announced on April 6, 2010 by issuing an additional 1,270,000 Units for gross proceeds of $76,200 
to qualified investors pursuant to applicable exemptions. Each Unit has a price of $0.06 and consists of one 
common share of the Company and one share purchase warrant (a "Warrant") entitling the holder to acquire one 
common share of the Company at an exercise price of $0.075 until April 23, 2011. Accordingly, the Company 
issued 1,270,000 common shares and 1,270,000 Warrants and has, subsequent to closing, 126,796,145 common shares 
issued and outstanding (the "Enlarged Share Capital"). An application has been made for the 1,270,000 common 
shares issued to be admitted to trading on AIM ("Admission"), and Admission is expected to occur on or about 
April 30, 2010. The common shares issued and the common shares issuable on exercise of the Warrants are subject 
to a regulatory hold period in Canada expiring August 24, 2010. 
 
The total number of voting rights attached to the Enlarged Share Capital on the basis of one vote per common 
share is 126,796,145. This voting rights figure may be used by shareholders of the Company as the denominator 
for the calculations by which they will determine whether they are required to notify their interests in, or a 
change to their interest in, the Company under the Disclosure and Transparency Rules of the Financial Security 
Authority (FSA) in the United Kingdom. 
 
This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the 
securities in the United States. The securities have not been and will not be registered under the U.S. 
Securities Act or any state securities laws and may not be offered or sold within the United States unless 
registered under the U.S. Securities Act and applicable state securities laws or an exemption from such 
registration is available. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the 
formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, 
with a research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebiopharma.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
[phone] 
[e-mail] 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Ryan Gaffney 
Nominated Adviser 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biopharma Corporation